Investment Partners Asset Management Inc. Raises Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Investment Partners Asset Management Inc. boosted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,132 shares of the exchange traded fund’s stock after purchasing an additional 210 shares during the period. Investment Partners Asset Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $282,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in XBI. Van ECK Associates Corp purchased a new stake in SPDR S&P Biotech ETF during the 4th quarter valued at $1,497,000. Viewpoint Capital Management LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter worth about $180,000. Certuity LLC boosted its holdings in shares of SPDR S&P Biotech ETF by 28.8% during the fourth quarter. Certuity LLC now owns 11,168 shares of the exchange traded fund’s stock worth $1,006,000 after purchasing an additional 2,494 shares during the period. Weatherly Asset Management L. P. grew its stake in shares of SPDR S&P Biotech ETF by 0.3% in the fourth quarter. Weatherly Asset Management L. P. now owns 157,945 shares of the exchange traded fund’s stock worth $14,225,000 after purchasing an additional 532 shares during the last quarter. Finally, Kingsview Wealth Management LLC increased its holdings in SPDR S&P Biotech ETF by 60.3% during the 4th quarter. Kingsview Wealth Management LLC now owns 6,350 shares of the exchange traded fund’s stock valued at $572,000 after purchasing an additional 2,388 shares during the period.

SPDR S&P Biotech ETF Price Performance

XBI opened at $89.97 on Thursday. SPDR S&P Biotech ETF has a one year low of $81.14 and a one year high of $105.47. The business has a 50 day simple moving average of $92.05 and a two-hundred day simple moving average of $96.25. The firm has a market capitalization of $6.86 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.